| # | Title | Authors | Keywords |
|---|---|---|---|
| P331 | A phase 1a clinical trial of NLG802, a prodrug of indoximod with enhanced pharmacokinetic properties | Olivier Rixe, MD, PhD; Thomas George, MD; Heloisa Soares; Agnieszka Marcinowicz; Nicholas Vahanian, MD; Charles Link, Jr., MD; Edouard Dupis; Eugene P. Kennedy, MD, FACS; Mario Mautino, PhD | Clinical study; Clinical trial; Immune suppression; Solid tumors |
